Literature DB >> 20427420

Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.

J Lado-Abeal1, R Celestino, S B Bravo, M E R Garcia-Rendueles, J de la Calzada, I Castro, P Castro, C Espadinha, F Palos, P Soares, C V Alvarez, M Sobrinho-Simões, J Cameselle-Teijeiro.   

Abstract

Our main objective was to search for mutations in candidate genes and for paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement in a well-differentiated angioinvasive follicular thyroid carcinoma (FTC) causing hyperthyroidism. DNA and RNA were extracted from the patient's thyroid tumor, as well as 'normal' thyroid tissue, and from peripheral blood lymphocytes (PBLs) of the patient, her daughter, and two siblings. Nuclear isolation was extracted from the patient's tumor, 'normal' thyroid tissue, PBLs, and uterine leiomyoma tissue. TSH receptor (TSHR), RAS, and BRAF genes were sequenced. We searched for PAX8-PPARgamma in thyroid, PBL, and uterine leiomyoma samples from the patient and family members. Proliferative effects of detected mutants on non-transformed human thyrocytes cultures. An activating TSHR mutation, M453T, was detected in the tumor. PAX8 (exons 1-8+10)-PPARgamma was found in all tested patient's tissues. A second rearrangement, PAX8 (exons 1-8)-PPARgamma, was detected in the patient's normal thyroid tissue. Under deprived medium condition, co-transfection of PAX8-PPARgamma and TSHR-M453T dramatically increased the number of thyrocytes, an effect that it was not observed with TSHR wild-type (WT); under complete medium conditions, co-transfection of PAX8-PPARgamma with either TSHR-M453T or TSHR-WT inhibited cell proliferation. We report a patient with hyperthyroidism due to a FTC bearing an activating TSHR mutation and PAX8-PPARgamma rearrangements. PAX8-PPARgamma was present as a mosaicism affecting tissues from endodermal and mesodermal origin. PAX8-PPARgamma and TSHR-M453T inhibited or promoted thyrocyte proliferation depending on medium conditions. The activating TSHR mutation could promote in vivo FTC development in PAX8-PPARgamma-positive thyrocytes under poor blood supply with deprivation of growth factors but restraint the tumor growth when growth factors are supplied.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427420     DOI: 10.1677/ERC-09-0069

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  6 in total

1.  Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma.

Authors:  Guo-Xia Tong; Qing Chang; Diane Hamele-Bena; John Carew; Richard S Hoffman; Marina N Nikiforova; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 2.  Pitfalls in Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers.

Authors:  José Manuel Cameselle-Teijeiro; Catarina Eloy; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2020-07-06       Impact factor: 3.943

3.  Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies.

Authors:  Haixia Guan; Danielle Matonis; Gianluca Toraldo; Stephanie L Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-25       Impact factor: 5.555

4.  Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis.

Authors:  Lorraine W Lau; Sana Ghaznavi; Alexandra D Frolkis; Alexandra Stephenson; Helen Lee Robertson; Doreen M Rabi; Ralf Paschke
Journal:  Thyroid Res       Date:  2021-02-25

5.  Hyperfunctioning Papillary Thyroid Carcinoma with a BRAF Mutation: The First Case Report and a Literature Review.

Authors:  Shinsuke Shinkai; Kenji Ohba; Kennichi Kakudo; Takayuki Iwaki; Yoshihiro Mimura; Akio Matsushita; Go Kuroda; Yuki Sakai; Nobuhiko Nishino; Kazuo Umemura; Takafumi Suda; Shigekazu Sasaki
Journal:  Eur Thyroid J       Date:  2021-03-05

6.  Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer.

Authors:  Zunfu Ke; Yihao Liu; Yunjian Zhang; Jie Li; Ming Kuang; Sui Peng; Jinyu Liang; Shuang Yu; Lei Su; Lili Chen; Cong Sun; Bin Li; Jessica Cao; Weiming Lv; Haipeng Xiao
Journal:  Oncol Rep       Date:  2018-06-14       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.